Potential Indications that PLX Cells may treat?

It is important to remember that the first 13 indications listed are from Pluristem's own website. I have researched the bone marrow recovery data myself and inserted a number that is current. 14 thru 18 are indications, that I personally feel may likely become future indications for Pluristem. They are my "opinion only" and are not taken from any past press releases from the company.

1.CLI-10 Billion Dollars (ALL PER YEAR->GLOBALLY)
2.IC- 4 Billion
3.Beurger's Disease- 2.5 Billion
4.Diabetic Foot Ulcers 1.5 Billion
5.Adjuvant Hip Replace/Muscle repair 1 Billion
6.Numerous Athletic Injuries 6 Billion
7.Pulmonary Hypertension 1 Billion
8.Inflammatory Bowel Disease 2 Billion
9.Multiple Sclerosis 8 Billion
10.Neuropathic Pain 3 Billion
11.Ischemic Stroke 8 Billion
12.Bone Marrow Recovery 10 Billion
13.Acute Radiation Sickness-Stockpiles- 2 billion

14.Burn Recovery 5 Billion
15.Cirrhosis of the Liver 2 Billion
16.Numerous Lung Indications 8 Billion
17 Numerous Cardiac Indications 12 Billion
18.Rheumatoid Arthritis 18 Billion

Total amount of global yearly Indications:104 Billion.

Granted these are huge numbers however, they are credible numbers that analyst may use to calculate future potential revenues on a macro scale in order to determine a baseline stock price based on a 3-5 year outlook which is what a longterm investor may consider when trying to determine a minimum stock price for their investment time horizon. Even if Pluristem's PLX Cells are effective in treating only 25% of these indications listed above over the next 3-5 years and beyond. One can easily see that the current stock price is a mere fraction of what it will be upon successful approval from the FDA/EMA. These numbers are "Food for Thought" only and are only ment to be used as a backdrop to Pluristem's future inherent potential as a leader in the treatment of the vast inflammatory/ischemic disease indications that afflict the global community.

Full-Disclosure: Buteo has been a stockholder in PSTI for a number of years and has only written these numbers for individuals who have not had the time nor the interest until recently to fully understand the magnitude of the inherent potential of PLX Cells upon the global medical community. The news today was again impressive however, not surprising to me as I expect many more to come in the coming months and years. This tiny Biotech stock is in my opinion only a "Sleeping Giant" and I believe the company is on the verge of a "major breakout" as in my opinion only the stock price should right now be trading in the $12-18 dollar range and will do so by the end of this year! Regards, Buteo-

P.S. Traders will add extreme volatility to the stock in the coming months however, long-term growth investors will be rewarded with the buy and hold approach as I believe Pluristem is "the premeir micro-cap biotech growth-stock investment of this decade"!